Clinical trial
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
NCT06845319
Study timeline
Study start (actual)2025-10-20Date precision: day
Registry last updated2026-05-06
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Triple Negative Breast Cancerunresolved
Interventions
CarboplatinDRUG · verified · RxNorm: carboplatin
PaclitaxelDRUG · verified · RxNorm: paclitaxel
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
Medical University of South Carolinalead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06845319 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.